Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on August 8, 2007
JNCI Journal of the National Cancer Institute 2007 99(16):1213; doi:10.1093/jnci/djm134
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/16/1213-b    most recent
djm134v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Savage, L.
Right arrow Articles by Widener, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Savage, L.
Right arrow Articles by Widener, A.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

MEMO TO THE MEDIA

Press Release

Chemotherapy with Bevacizumab Increases Risk of Blood Clots in Arteries

Liz Savage, Andrea Widener

jncimedia{at}oxfordjournals.org
301-841-1287

Treatment with chemotherapy and bevacizumab, an anticancer drug, is associated with a greater risk of blood clots in patients’ arteries compared with treatment with chemotherapy only, according to a study published online August 7 in the Journal of the National Cancer Institute.

The combination of chemotherapy and bevacizumab has been shown to increase survival in patients with metastatic colorectal and non–small-cell lung cancer, but some previous studies suggest these patients are at an increased risk for blood clots in their arteries.

Frank Scappaticci, M.D., Ph.D., of Genentech, Inc. in South San Francisco, Calif., and colleagues analyzed data from five randomized controlled trials that included 1,745 patients with metastatic colorectal, breast, or non–small-cell lung cancer.

Among patients treated with the combination therapy, 3.8 percent experienced blood clots in their arteries, compared with 1.7 percent of patients on chemotherapy alone.

There was no statistically significant difference in the incidence of blood clots in veins. Risk factors for blood clots in both arteries and veins included previous blood clots and older age (65 or older.)

"The clinical benefit associated with bevacizumab therapy was maintained for all subgroups. Although death from [a blood clot in the artery] was uncommon, we did not capture functional disabilities from these events, and the risk factors...identified in this study should be considered when making treatment decisions for individual patients," the authors write.

Note: Some of the data from this study was presented at the annual meeting of the American Society of Clinical Oncology in 2005.

Contact:

  • Edward J. Lang Jr., product and patient advocacy communications manager, Genentech, lang.edward{at}gene.com, (650) 467-8606

Citations:

  • Scappaticci FA, Skillings JR, Holden SN, Gerber H-P, Miller K, et al. Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab. J Natl Cancer Inst 2007; 99:1232–1239

Note to Reporters:

We are starting up an e-mail list to alert reporters when papers are available on the EurekAlert site. If you would be interested on being on this list, please let us know at jncimedia{at}oxfordjournals.org. The content will continue to be available through EurekAlert's e-mail system and our EurekAlert page.

The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jnci.oxfordjournals.org/.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab
Frank A. Scappaticci, Jamey R. Skillings, Scott N. Holden, Hans-Peter Gerber, Kathy Miller, Fairooz Kabbinavar, Emily Bergsland, James Ngai, Eric Holmgren, Jiuzhou Wang, and Herbert Hurwitz
J Natl Cancer Inst 2007 99: 1232-1239. [Abstract] [Full Text] [PDF]




This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/16/1213-b    most recent
djm134v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Savage, L.
Right arrow Articles by Widener, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Savage, L.
Right arrow Articles by Widener, A.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?